Shares in Stratagene dropped to a 52-week low of $5.40 late last week, a few days after the firm posted a second-quarter loss. Despite the announcement earlier this week of a collaboration with Merck unit Rosetta Inpharmatics (see related article), Stratagene’s shares regained little ground, closing Tuesday at $5.49, down 19.7 percent for the tracking period.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Andy Page, the former president of 23andMe, has joined a diabetes-management startup, according to CNBC.

In Cell this week: regulatory changes in pancreatic cancer, metabolic shifts in Alzheimer's disease, and more.

NPR reports that Turkish high school students will no longer study evolution.

Researchers report they sequenced and identified plant species in an "al fresco" laboratory.